The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions
Abstract
AKT is frequently activated in various cancers, but its involvement in lung tumor development and progression is not well established. We examined AKT activity by immunohistochemistry in 110 non-small cell lung carcinomas (NSCLCs) using tissue microarrays. AKT activation was observed in 56 (51%) tumors. To further validate activation of the AKT pathway in this series, we examined the phosphorylation status of the mammalian target of rapamycin (mTOR) and forkhead (FKHR), two downstream targets of AKT. Positive staining for phospho-mTOR and phospho-FKHR were detected in 74% and 68% of tumors, respectively, and was significantly associated with activation of AKT. Tumors positive for phosphorylated (active) AKT were present with a similar frequency in low stage (I/II) and high stage (III/IV) tumors, raising the possibility that AKT activation occurs early in tumor progression. We therefore examined AKT activity in 25 bronchial epithelial lesions from 12 patients at high risk of lung cancer. Metaplastic/dysplastic areas showed AKT activity, whereas normal and hyperplastic bronchial epithelia exhibited little or no activity. Since some bronchial epithelial lesions may develop into invasive cancers, we examined the effect of AKT on invasiveness of lung cancer cells, using an in vitro cell invasion assay. Transfection of NSCLC cells with wild-type AKT increased invasiveness in response to hepatocyte growth factor, whereas transfection with dominant negative AKT abrogated this effect. Collectively, these data suggest that AKT activation is a frequent and early event in lung tumorigenesis, which may enhance risk of progression to malignancy. Thus, AKT represents a potentially important target for chemoprevention in individuals at high risk of NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Mechanisms and consequences of activation of protein kinase B/Akt
Downward, J. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80149-x · Cited by 1,303
Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation
COFFER, P. J., JIN, J., & WOODGETT, J. R. (1998) · Biochemical Journal · doi:10.1042/bj3350001 · Cited by 1,067
Brognard, J., Clark, A. S., Ni, Y., & Dennis, P. A. (2001) · PubMed · Cited by 987
AKT plays a central role in tumorigenesis
Testa, J. R., & Bellacosa, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211430998 · Cited by 944
Self-citationChan, T. O., Rittenhouse, S. E., & Tsichlis, P. N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.965 · Cited by 737
Julien-Grille, S., Bellacosa, A., Upson, J. J., Klein–Szanto, A. J., Roy, F. M. V., Lee‐Kwon, W., Donowitz, M., Tsichlis, P. N., & Larue, L. (2003) · PubMed · Cited by 701
West, K. A., Brognard, J., Clark, A. S., Linnoila, I. R., Yang, X., Swain, S. M., Harris, C. C., Belinsky, S. A., & Dennis, P. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16147 · Cited by 576
Arboleda, M. J., Lyons, J. F., Kabbinavar, F. F., Bray, M. R., Snow, B. E., Ayala, R., Danino, M., Karlan, B. Y., & Slamon, D. J. (2003) · PubMed · Cited by 507
Sun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z.-Q., Ma, X.-L., Shelley, S. A., Jove, R., Tsichlis, P. N., Nicosia, S. V., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61714-2 · Cited by 454
Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology.
Hirsch, F. R., Franklin, W. A., Gazdar, A. F., & Bunn, P. A. (2001) · PubMed · Cited by 398
Yuan, Z. Q., Sun, M., Feldman, R. I., Wang, G., Ma, X.-L., Jiang, C., Coppola, D., Nicosia, S. V., & Cheng, J. Q. (2000) · Oncogene · doi:10.1038/sj.onc.1203598 · Cited by 384
Lung cancer : principles and practice
Pass, H. I. (1996) · Cited by 357
Janmaat, M. L., Kruyt, F. A. E., Rodríguez, J. A., & Giaccone, G. (2003) · PubMed · Cited by 356
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis
Roy, H. K. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.201 · Cited by 343
Tumor Invasion: Role of Growth Factor-Induced Cell Motility
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)61023-4 · Cited by 330
A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt
Aoki, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.011528498 · Cited by 303
Hepatocyte growth factor/scatter factor—Met signaling in tumorigenicity and invasion/metastasis
Jeffers, M., Rong, S., & Vande Woude, G. F. (1996) · Journal of Molecular Medicine · doi:10.1007/bf00204976 · Cited by 288
Chun, K.-H., Kosmeder, J. W., Sun, S., Pezzuto, J. M., Lotan, R., Hong, W. K., & Lee, H.-Y. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.4.291 · Cited by 255
Inhibition of protein kinase B/Akt
Hill, M. M., & Hemmings, B. A. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00193-6 · Cited by 245
TANNO, S., TESTA, J., & KOHGO, Y. (2001) · Gastroenterology · doi:10.1016/s0016-5085(01)80193-1 · Cited by 241
Olivero, M., Rizzo, M., Madeddu, R., Casadio, C., Pennacchietti, S., Nicotra, M., Prat, M., Maggi, G., Arena, N., Natali, P., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.646 · Cited by 199
Frequent activation of AKT2 kinase in human pancreatic carcinomas
Altomare, D. A., Tanno, S., De Rienzo, A., Klein‐Szanto, A. J., Tanno, S., Skele, K. L., Hoffman, J. P., & Testa, J. R. (2002) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10287 · Cited by 174
Tsao, A. S., McDonnell, T. J., Lam, S. C., Putnam, J. B., Bekele, N. B., Hong, W. K., & Kurie, J. M. (2003) · PubMed · Cited by 128
Tsao, M., Liu, G., Chen, J.-R., et al. (1998) · Lung Cancer · doi:10.1016/s0169-5002(98)00007-5 · Cited by 123
Okano, J., Shiota, G., Matsumoto, K., Yasui, S., Kurimasa, A., Hisatome, I., Steinberg, P., & Murawaki, Y. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.04.002 · Cited by 110
Nakashio, A., Fujita, N., Rokudai, S., Sato, S., & TSURUO, T. (2000) · PubMed · Cited by 96
Testa, J. R., Siegfried, J. M., Liu, Z., Hunt, J. D., Feder, M., Litwin, S., Zhou, J., Taguchi, T., & Keller, S. M. (1994) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870110307 · Cited by 85
Kotelevets, L., Noë, V., Bruyneel, E. A., Mysiakine, E., Chastre, E., Mareel, M., & Gespach, C. P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14138 · Cited by 71
Translocation and activation of AKT2 in response to stimulation by insulin.
Mitsuuchi, Y., Johnson, S. W., Moonblatt, S., & Testa, J. R. (1998) · PubMed · Cited by 30
Growth factors and lung cancer
Sethi, T., & Woll, P. J. (1994) · Cancer treatment and research · doi:10.1007/978-1-4615-2630-8_5 · Cited by 10
Cited by
Perturbations of the AKT signaling pathway in human cancer
Altomare, D. A., & Testa, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209085 · Cited by 1,329
Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
(2005) · Advances in Cancer Research · doi:10.1016/s0065-230x(05)94002-5 · Cited by 823
Oncogenic PI3K deregulates transcription and translation
Bader, A. G., Kang, S., Zhao, L., & Vogt, P. K. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1753 · Cited by 798
The relation between PI3K/AKT signalling pathway and cancer
Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S., & Baradaran, B. (2019) · Gene · doi:10.1016/j.gene.2019.02.076 · Cited by 651
Phosphorylation of Mammalian Target of Rapamycin (mTOR) at Ser-2448 IsMediated by p70S6 Kinase
Chiang, G. G., & Abraham, R. T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501707200 · Cited by 562
Metadata
- Authors
- Balsara, B. R.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-06-03
- Volume
- 25
- Issue
- 11
- Pages
- 2053-2059
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2132292320
- Cited by
- 295
- References
- 32
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.